Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MESO Mesoblast	$10.89 -0.3%	$11.33	$5.78 ▼ $22.00	$1.40B	2.41	274,764 shs	114,123 shs
PASG Passage Bio	$0.40 +20.9%	$0.37	$0.26 ▼ $5.75	$20.58M	1.71	372,795 shs	606,213 shs
PCVX Vaxcyte	$32.51 -0.2%	$33.26	$27.66 ▼ $121.06	$4.20B	1.2	1.47 million shs	1.58 million shs
STRO Sutro Biopharma	$0.71 -2.7%	$0.88	$0.52 ▼ $5.17	$61.99M	1.7	1.14 million shs	722,075 shs
TSHA Taysha Gene Therapies	$2.31 -2.9%	$2.43	$1.05 ▼ $3.31	$510.89M	1.03	2.92 million shs	1.32 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MESO Mesoblast	0.00%	+4.60%	+2.92%	-12.50%	+60.35%
PASG Passage Bio	0.00%	-15.32%	-23.02%	-6.23%	-58.31%
PCVX Vaxcyte	0.00%	-0.88%	-0.06%	-13.72%	-56.85%
STRO Sutro Biopharma	0.00%	-8.35%	-18.63%	+12.82%	-74.95%
TSHA Taysha Gene Therapies	0.00%	-3.25%	-12.18%	+71.22%	+6.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MESO Mesoblast	1.8828 of 5 stars	3.5	1.0	0.0	2.3	0.8	0.6
PASG Passage Bio	2.8484 of 5 stars	3.5	3.0	0.0	1.6	1.7	1.3
PCVX Vaxcyte	1.8867 of 5 stars	3.6	1.0	0.0	2.6	1.7	0.0
STRO Sutro Biopharma	3.8155 of 5 stars	3.1	1.0	4.7	3.8	1.7	0.0
TSHA Taysha Gene Therapies	3.2213 of 5 stars	4.5	1.0	0.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MESO Mesoblast	3.00	Buy	$18.00	65.29% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,773.59% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	319.87% Upside
STRO Sutro Biopharma	2.25	Hold	$6.11	756.46% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.00	246.32% Upside

Current Analyst Ratings Breakdown

Latest MESO, TSHA, PASG, PCVX, and STRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MESO Mesoblast	$5.90M	235.85	N/A	N/A	$4.21 per share	2.59
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
STRO Sutro Biopharma	$62.04M	0.97	N/A	N/A	$0.54 per share	1.32
TSHA Taysha Gene Therapies	$8.33M	59.53	N/A	N/A	$0.35 per share	6.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)
STRO Sutro Biopharma	-$227.46M	-$2.98	N/A	N/A	N/A	-373.66%	-347.60%	-59.46%	8/12/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest MESO, TSHA, PASG, PCVX, and STRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MESO Mesoblast	0.22	0.96	0.63
PASG Passage Bio	N/A	3.74	3.74
PCVX Vaxcyte	N/A	17.70	17.70
STRO Sutro Biopharma	N/A	2.16	2.16
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MESO Mesoblast	1.43%
PASG Passage Bio	53.48%
PCVX Vaxcyte	96.78%
STRO Sutro Biopharma	96.99%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
MESO Mesoblast	18.80%
PASG Passage Bio	4.30%
PCVX Vaxcyte	3.10%
STRO Sutro Biopharma	5.90%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
PASG Passage Bio	130	62.15 million	59.48 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable
STRO Sutro Biopharma	240	84.46 million	79.48 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

MESO, TSHA, PASG, PCVX, and STRO Headlines

Recent News About These Companies

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

June 29 at 4:08 AM | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26, 2025 | marketbeat.com

Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $7.57

June 24, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 4, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?
By Jeffrey Neal Johnson | June 4, 2025
View Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?
Why Amazon Could Be About To Breakout To $250
By Sam Quirke | June 19, 2025
View Why Amazon Could Be About To Breakout To $250
Jabil Stock Hits Highs on AI Tailwinds and Strong Buybacks
By Thomas Hughes | June 18, 2025
View Jabil Stock Hits Highs on AI Tailwinds and Strong Buybacks

MESO, TSHA, PASG, PCVX, and STRO Company Descriptions

Mesoblast NASDAQ:MESO

$10.89 -0.03 (-0.27%)

As of 04:00 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Passage Bio NASDAQ:PASG

$0.40 +0.07 (+20.90%)

As of 04:00 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Vaxcyte NASDAQ:PCVX

$32.51 -0.07 (-0.21%)

As of 04:00 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sutro Biopharma NASDAQ:STRO

$0.71 -0.02 (-2.74%)

As of 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Taysha Gene Therapies NASDAQ:TSHA

$2.31 -0.07 (-2.94%)

As of 04:00 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time